Association of Statin Exposure With Histologically Confirmed Idiopathic Inflammatory Myositis in an Australian Population

Abstract

IMPORTANCE Statin medications are widely prescribed for cardiovascular risk reduction. Myalgia and rhabdomyolysis are well-recognized adverse effects of statins, and they resolve with the cessation of statin therapy. Idiopathic inflammatory myositis (IIM) is a heterogeneous group of autoimmune myopathies that may also be associated with statin use. Recently, statin-associated autoimmune myopathy has been recognized as a distinct entity with the presence of specific autoantibodies against hydroxymethylglutaryl-coenzyme A reductase, which results in a necrotizing myositis that does not resolve with cessation of statin therapy and requires treatment with immunosuppressive agents. OBJECTIVE To examine the association between histologically confirmed IIM and current exposure to statin medications. DESIGN, SETTING, AND PARTICIPANTS Population-based case-control study using the South Australian Myositis Database of all histologically confirmed cases of IIM diagnosed between 1990 and 2014 in patients 40 years or older (n = 221) and population-based controls from the North West Adelaide Health Study (n = 662), matched by age and sex in a 3:1 ratio of controls to cases. Data analysis using conditional logistic regression was performed from June 1, 2016, to July 14, 2017. EXPOSURES Current statin medication use. MAIN OUTCOMES AND MEASURES Unadjusted and adjusted (for diabetes and cardiovascular disease) odds ratios and 95% CIs for likelihood of inflammatory myositis. RESULTS A total of 221 IIM cases met the inclusion criteria with a mean (SD) age of 62.2 (10.8) years, and 132 (59.7%) were female. Statin exposure at the time of IIM diagnosis was 68 of 221 patients (30.8%) and 142 of 662 matched controls (21.5%) (P = .005). There was an almost 2-fold increased likelihood of statin exposure in patients with IIM compared with controls (adjusted odds ratio, 1.79; 95% CI, 1.23-2.60; P = .001). Similar results were observed when patients with necrotizing myositis were excluded from the analysis (adjusted odds ratio, 1.92; 95% CI, 1.29-2.86; P = .001). CONCLUSIONS AND RELEVANCE In this large population-based study, statin exposure was significantly associated with histologically confirmed IIM. Given the increased use of statins worldwide and the severity of IIM, increased awareness and recognition of this potentially rare adverse effect of statin exposure is needed.

The effects of statins on microglial cells to protect against neurodegenerative disorders: A mechanistic review

“…Moreover, the efficacy of statin to prevent cardiovascular events outweighs the overall rare adverse effects. [10][11][12][13] Glia is a term derived from a Greek word meaning to glue or to stick together. Glial cells or neuroglia are the nonneuronal cells in the CNS, including astroglia, oligodendroglia, and microglia.…”

“…Despite of the therapeutic effects of statins, they have also potential adverse and side effects including increasing the risk of diabetes mellitus (except pitavastatin), myopathy/myalgia (most frequent side effect with documented rates from 1 to 10%), rhabdomyolysis (documented rates of 0.1%), hepatotoxicity, cataracts, increase the liver enzymes and statin‐related cognitive impairment. Moreover, the efficacy of statin to prevent cardiovascular events outweighs the overall rare adverse effects …”

Polymyositis, Dermatomyositis, and Statins: A Review

“…Exposure to statins was found in 30.3% of PM and in 17.4% of DM, thereby highlighting an almost 2-fold increased likelihood compared with controls. However, details on the type of statin, dosage, or duration of statin exposure was not available in this study [58].…”

Myopathy in a 61-year-old Hispanic man

“…However, the markedly positive anti-HMGCR antibodies and the pauci-immune necrosis on histology were most consistent with IMNM. Since IMNM has been associated with statin exposure, the inciting trigger of our patient’s illness was most likely the atorvastatin he was taking for his coronary artery disease 7…”